Press & media
Press & media
Everything a journalist needs to describe Vanguard Biotech Systems and NextGenAMR accurately, drawn from approved statements. For interviews, materials or clarifications, use the press contact below.
Please note when writing about NextGenAMR
To describe the product accurately, please do NOT present NextGenAMR as any of the following:
- NextGenAMR is not presented as an autonomous diagnostic system; it is designed to organise genomic evidence and generate outputs for professional review.
- NextGenAMR does not replace phenotypic antimicrobial susceptibility testing (AST). Genomic outputs must be interpreted together with AST, microbiological context and applicable procedures.
- NextGenAMR does not select treatments and does not generate autonomous therapeutic recommendations. Clinical decisions remain with qualified professionals.
Corporate boilerplate
Vanguard Biotech Systems is a Spanish biotechnology software company developing genomic intelligence systems for antimicrobial resistance. It was incorporated as a Sociedad de Responsabilidad Limitada (S.L.) in 2025, with its operational base in Granada and its registered office in Lepe, Huelva. NextGenAMR is the first product developed by Vanguard Biotech Systems. Juan Manuel Gómez Vargas — Founder of Vanguard Biotech Systems; leads NextGenAMR development.
About the company
Vanguard Biotech Systems is a Spanish biotechnology software company developing genomic intelligence systems for antimicrobial resistance. It was incorporated as a Sociedad de Responsabilidad Limitada (S.L.) in 2025, with its operational base in Granada and its registered office in Lepe, Huelva.
About the company →About NextGenAMR
NextGenAMR is the first product developed by Vanguard Biotech Systems. NextGenAMR is a genomic antimicrobial-resistance intelligence platform in development by Vanguard Biotech Systems. First species: Escherichia coli, in development. No performance results have been published. Not for clinical use; it has no regulatory authorisation or declaration of conformity for clinical diagnostic use.
In development. The E. coli engine is being built and will be evaluated internally under a pre-specified protocol. An independent external validation protocol has been drafted. No performance results have been published. Not for clinical use.
Company facts
- Incorporation and location
- Incorporated in 2025 (registered office: Lepe, Huelva); operational base: Granada, Spain
- Founder
- Juan Manuel Gómez Vargas — Founder of Vanguard Biotech Systems; leads NextGenAMR development.
- First product
- NextGenAMR is the first product developed by Vanguard Biotech Systems.
Media assets
Logos, authorised photographs and additional materials are available on request through the press contact. We do not publish brand assets or internal materials without authorisation.
Press contact
Write to us through the contact page with “Press” in the subject. We reply according to the request.